FDA 加速批准质粒 DNA 免疫疗法 Voceryq,减少复发性呼吸道乳头状瘤病患者的手术切除频率
Novel Therapy Lands Speedy Approval for Wart-Like Airway Disease
FDA 加速批准质粒 DNA 免疫疗法 doruxapapogene ralaplasmid-lalikinogene sifuplasmid(Voceryq),用于减少复发性呼吸道乳头状瘤病(RRP)成人患者的手术切除频率。
原文明确交代该药获加速批准所依据的 I/II 期试验数据,并提及既往获批药物,读者可据此了解 RRP 治疗药物选择的扩展。
— Plasmid DNA-based immunotherapy reduced surgery need in recurrent respiratory papillomatosis
November 2, 2026 • 2 min read
The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP), the agency announced late on Friday.
As the first FDA-approved recombinant plasmid DNA-based immunotherapy, doruxapapogene ralaplasmid-lalikinogene sifuplasmid targets the wart-like growths that characterize RRP. The growths are caused by human papillomavirus (HPV) and develop in the airways, particularly around the larynx. Severe cases of the rare disease can spread into the respiratory tract and make breathing difficult. There is no cure, but repeated surgeries can remove growths if they return.
FDA based its decision on efficacy data from RRP-001, a phase I/II clinical trial. The open-label trial included 32 patients who'd undergone at least two surgeries in the prior year to remove RRP growths. Among 26 patients who had at least three surgeries in the 12 months before treatment, 27% had a complete response to the plasmid therapy, defined as requiring no surgical excisions during 12 months of follow-up.
"The approval of Voceryq is an important step in improving the quality of life for RRP patients as every surgery carries the risk of laryngeal injury," said investigator Simon Best, MD, of Johns Hopkins University in Baltimore, in a statement from manufacturer Inovio Pharmaceuticals. "I believe it is in the best interest of RRP patients that the standard of care quickly transition away from surgical interventions to immunotherapy after RRP is diagnosed."
Doruxapapogene ralaplasmid-lalikinogene sifuplasmid includes two plasmids that contain genetic coding for HPV proteins and interleukin 12. Patients' own healthy cells transcribe that coding to stimulate immune system attacks against cells infected with the HPV types 6 and 11 that cause RRP.
The therapy's treatment regimen begins with surgical debulking of visible papilloma, followed by an intramuscular dose of the plasmid therapy every 3 weeks for a total of four doses. Label warnings include potential adverse events (AEs) such as muscle contractions, transient bleeding, and vasovagal reactions. The most common AEs in trials included injection site reactions, headache, fatigue, hypertension, nausea, and dizziness.
The new treatment was approved in combination with a proprietary DNA medicine delivery device (CELLECTRA 5PSP). Postmarketing trials will be required to verify and describe the therapy's clinical benefit.
The FDA approved the immunotherapy zopapogene imadenovec (Papzimeos) for RRP in 2025, the first approved medical therapy for the condition.
来源:MedPage Today · medpagetoday.com